MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: December 15, 2016
Date CME Credit No Longer Available: December 15, 2018

Learning Objectives

At the conclusion of this course, participants should be able to:

1. Summarize the ongoing work in disease-modifying therapies for Parkinson's disease.
2. Describe what is known about cellular connections underlying Parkinson's disease.
3. Recognize Parkinson's symptomatic treatments that are at or near market.
4. Discuss the state of research into tools and tests that could diagnose and track Parkinson's.
5. List updates on research related to deep brain stimulation (DBS), stem cells and exercise.   

Target Audience

This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Faculty

Dave Iverson
No disclosures

Rachel Dolhun, MD
No disclosures

Todd Sherer, PhD
No disclosures

Gary Rafaloff
Advisory Role: Acorda Therapeutics; Takeda Pharmaceuticals; Biotie Therapies; PatientsLikeMe; Merck
Ownership Interests: Anavex Life Sciences